Enhanced Delivery and Potency of Chemotherapeutics in Melanoma Treatment Via Magnetite Nanobioconjugates

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2024 Nov 18

PMID 39554413

Authors

Erika Diaz

Valentina Quezada

Javier Cifuentes

Nydia Yadira Arias Morales

Luis H Reyes

Carolina Munoz-Camargo

Juan C Cruz

Affiliations

Soon will be listed here.

Abstract

Melanoma, known for its aggressive metastatic potential, poses significant treatment challenges. Despite the potent antiproliferative effects of anticancer drugs, systemic toxicity and low water solubility limit their efficacy. This study addresses these challenges by employing magnetite (FeO) nanobioconjugates as a drug delivery system, aimed at enhancing drug solubility and reducing off-target effects in melanoma therapy. Magnetite nanoparticles (MNPs) were engineered with functional molecules and loaded with the anticancer agents Temozolomide (TMZ) or paclitaxel (PTX). The nanobioconjugates were characterized via Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), dynamic light scattering (DLS), and transmission electron microscopy (TEM). The results validated the efficacious synthesis and drug loading, attaining efficiencies ranging from 32 to 72% for TMZ and 32 to 60% for PTX. Biocompatibility assessments demonstrated excellent tolerance, with minimal hemolysis rates and platelet aggregation. In vitro studies revealed enhanced cytotoxicity against A-375 human melanoma cells compared to free drugs, with cellular uptake facilitated primarily through macropinocytosis, caveolin-, and clathrin-mediated endocytosis. Furthermore, the nanobioconjugates exhibited significant efficacy in targeting A-375 melanoma spheroids, underlining their potential in melanoma therapy. This research underscores magnetite nanobioconjugates as a promising avenue for targeted melanoma treatment, offering enhanced drug delivery specificity and reduced systemic toxicity in oncological drug delivery systems.

References

Mascolo M, Pei Y, Ring T . Room Temperature Co-Precipitation Synthesis of Magnetite Nanoparticles in a Large pH Window with Different Bases. Materials (Basel). 2017; 6(12):5549-5567. PMC: 5452734. DOI: 10.3390/ma6125549. View

Mahoney B, Raghunand N, Baggett B, Gillies R . Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 2003; 66(7):1207-18. DOI: 10.1016/s0006-2952(03)00467-2. View

Tang T, Valenzuela A, Petit F, Chow S, Leung K, Gorin F . MRI of Functionalized Iron Oxide Nanoparticles for Brain Inflammation. Contrast Media Mol Imaging. 2018; 2018:3476476. PMC: 6036843. DOI: 10.1155/2018/3476476. View

Johnson B, Charman W, Porter C . An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci. 2003; 4(4):E40. PMC: 2751329. DOI: 10.1208/ps040440. View

Zeng H, Li J, Hou K, Wu Y, Chen H, Ning Z . Melanoma and Nanotechnology-Based Treatment. Front Oncol. 2022; 12:858185. PMC: 8959641. DOI: 10.3389/fonc.2022.858185. View

Munoz L, Jaramillo V, Gantiva-Diaz M, Cifuentes J, Munoz-Camargo C, Cruz J . Formulation of a novel antibacterial topical treatment based on Magnetite-Buforin-II-silver nanobioconjugates. Front Bioeng Biotechnol. 2022; 10:1003004. PMC: 9649911. DOI: 10.3389/fbioe.2022.1003004. View

Feng Q, Liu Y, Huang J, Chen K, Huang J, Xiao K . Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings. Sci Rep. 2018; 8(1):2082. PMC: 5794763. DOI: 10.1038/s41598-018-19628-z. View

Ghazanfari M, Kashefi M, Shams S, Jaafari M . Perspective of Fe3O4 Nanoparticles Role in Biomedical Applications. Biochem Res Int. 2016; 2016:7840161. PMC: 4884576. DOI: 10.1155/2016/7840161. View

Ramirez-Acosta C, Cifuentes J, Castellanos M, Moreno R, Munoz-Camargo C, Cruz J . PH-Responsive, Cell-Penetrating, Core/Shell Magnetite/Silver Nanoparticles for the Delivery of Plasmids: Preparation, Characterization, and Preliminary Evaluation. Pharmaceutics. 2020; 12(6). PMC: 7356180. DOI: 10.3390/pharmaceutics12060561. View

10.

Jang J, Kim M, Lee J, Kim S, Cho J . Enhancement of the cancer targeting specificity of buforin IIb by fusion with an anionic peptide via a matrix metalloproteinases-cleavable linker. Peptides. 2011; 32(5):895-9. DOI: 10.1016/j.peptides.2011.02.010. View

11.

Rueda-Gensini L, Cifuentes J, Castellanos M, Puentes P, Serna J, Munoz-Camargo C . Tailoring Iron Oxide Nanoparticles for Efficient Cellular Internalization and Endosomal Escape. Nanomaterials (Basel). 2020; 10(9). PMC: 7559083. DOI: 10.3390/nano10091816. View

12.

Rizvi S, Saleh A . Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018; 26(1):64-70. PMC: 5783816. DOI: 10.1016/j.jsps.2017.10.012. View

13.

Revia R, Zhang M . Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances. Mater Today (Kidlington). 2016; 19(3):157-168. PMC: 4981486. DOI: 10.1016/j.mattod.2015.08.022. View

14.

Wesolowski J, Rajdev P, Mukherji S . Temozolomide (Temodar). AJNR Am J Neuroradiol. 2010; 31(8):1383-4. PMC: 7966084. DOI: 10.3174/ajnr.A2170. View

15.

Sun S, Zu X, Tuo Q, Chen L, Lei X, Li K . Caveolae and caveolin-1 mediate endocytosis and transcytosis of oxidized low density lipoprotein in endothelial cells. Acta Pharmacol Sin. 2010; 31(10):1336-42. PMC: 4012904. DOI: 10.1038/aps.2010.87. View

16.

Wang B, Zhang L, Bae S, Granick S . Nanoparticle-induced surface reconstruction of phospholipid membranes. Proc Natl Acad Sci U S A. 2008; 105(47):18171-5. PMC: 2587577. DOI: 10.1073/pnas.0807296105. View

17.

Gavas S, Quazi S, Karpinski T . Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021; 16(1):173. PMC: 8645667. DOI: 10.1186/s11671-021-03628-6. View

18.

Bohmer N, Jordan A . Caveolin-1 and CDC42 mediated endocytosis of silica-coated iron oxide nanoparticles in HeLa cells. Beilstein J Nanotechnol. 2015; 6:167-76. PMC: 4311761. DOI: 10.3762/bjnano.6.16. View

19.

Subhan M, Yalamarty S, Filipczak N, Parveen F, Torchilin V . Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. J Pers Med. 2021; 11(6). PMC: 8234032. DOI: 10.3390/jpm11060571. View

20.

Wei Y, Tang T, Pang H . Cellular internalization of bystander nanomaterial induced by TAT-nanoparticles and regulated by extracellular cysteine. Nat Commun. 2019; 10(1):3646. PMC: 6692393. DOI: 10.1038/s41467-019-11631-w. View